TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a Cancer-Testis Antigen (CTA)
which is expressed in various tumors. After selected the high affinity TCR gene to NY-ESO-1,
the researchers insert genes into the cell that expressing a kind of protein that targeting
NY-ESO-1. Then the engineered cells are re-infused in the patients with tumors for curing the
tumor patient or prolonging life.